Related Experiment Video
Updated: Feb 14, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
Published on: June 27, 2025
Persistent Pulmonary Hypertension and Histologic Chorioamnionitis in Preterm Infants: Controlled Study.
N Katz1,2,3, Y Bar-Or4, A Raucher-Sterrnfeld5
1Neonatal Intensive Care Unit, Wolfson Medical Center, Holon, Israel. Kneri@WMC.gov.il.
This study found no association between histologic chorioamnionitis and persistent pulmonary hypertension of the newborn (PPHN) in preterm infants. Further research is needed to understand PPHN causes in this vulnerable population.
Area of Science:
- Neonatal Medicine
- Perinatal Pathology
Background:
- Persistent pulmonary hypertension of the newborn (PPHN) is a critical condition with high morbidity and mortality.
- Understanding the etiology of PPHN in preterm infants is crucial for improving outcomes.
Purpose of the Study:
- To investigate the potential association between histologic chorioamnionitis (HCA) and the incidence of echocardiographically confirmed PPHN in preterm infants.
- To identify risk factors contributing to PPHN in this specific patient group.
Main Methods:
- A case-control study involving 27 preterm infants with PPHN and 27 matched controls.
- Data collected included respiratory support, oxygen supplementation, duration of membrane rupture, and maternal/neonatal clinical data.
- Placental examination for HCA and statistical analysis using t-tests, Kolmogorov-Smirnov, and Chi-square tests.
Main Results:
- No statistically significant differences were observed between the PPHN and control groups in most parameters.
- The PPHN group showed a higher utilization of oxygen supplementation.
- No association was found between HCA and PPHN in preterm infants within the first three days of life.
Conclusions:
- Histologic chorioamnionitis does not appear to be a significant factor in the development of PPHN in preterm infants within the first three days of life.
- The underlying causes of PPHN in this population require further investigation.
- Oxygen supplementation was a notable difference in PPHN management.
More Related Videos
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Hypertension III: Clinical Manifestations and Diagnostic Studies

